statistiche ricercatore

Continente	#
AS - Asia	487
NA - Nord America	352
EU - Europa	320
SA - Sud America	57
AF - Africa	27
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.245

Nazione	#
US - Stati Uniti d'America	337
SG - Singapore	203
RU - Federazione Russa	154
VN - Vietnam	105
CN - Cina	92
IT - Italia	54
BR - Brasile	48
DE - Germania	33
HK - Hong Kong	31
FR - Francia	17
FI - Finlandia	13
GB - Regno Unito	10
NL - Olanda	10
CA - Canada	9
IN - India	9
ZA - Sudafrica	9
JP - Giappone	8
BD - Bangladesh	7
CI - Costa d'Avorio	7
KR - Corea	7
AR - Argentina	6
PK - Pakistan	6
PL - Polonia	6
IE - Irlanda	5
PH - Filippine	5
AT - Austria	4
TR - Turchia	4
IQ - Iraq	3
LV - Lettonia	3
MA - Marocco	3
MX - Messico	3
CR - Costa Rica	2
EG - Egitto	2
SE - Svezia	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
AO - Angola	1
AU - Australia	1
BE - Belgio	1
BN - Brunei Darussalam	1
CG - Congo	1
CH - Svizzera	1
CL - Cile	1
CW - ???statistics.table.value.countryCode.CW???	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
ES - Italia	1
ET - Etiopia	1
GA - Gabon	1
GR - Grecia	1
HR - Croazia	1
ID - Indonesia	1
KE - Kenya	1
KZ - Kazakistan	1
MZ - Mozambico	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
TH - Thailandia	1
UA - Ucraina	1
Totale	1.245

Nome	#
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data	190
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort	176
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort	158
A third-line sorafenib aftrer sequential therapy with sunitinib and mTOR inhibitors in methastatic renal cell carcinoma	153
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination	147
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study	119
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome	107
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice	106
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study	104
Totale	1.260

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	32	0	0	0	0	0	1	0	0	3	3	12	13
2022/2023	59	5	2	0	6	10	8	1	4	6	11	6	0
2023/2024	56	0	7	8	3	6	5	0	12	2	3	6	4
2024/2025	369	9	4	1	11	22	20	29	23	23	36	155	36
2025/2026	702	75	59	72	60	104	35	111	28	85	57	16	0
Totale													1.260